CTI BioPharma Corp. (CTIC)

2.35
NASDAQ : Health Technology
Prev Close 2.27
Day Low/High 2.17 / 2.36
52 Wk Low/High 2.17 / 5.36
Avg Volume 537.00K
Exchange NASDAQ
Shares Outstanding 57.98M
Market Cap 131.61M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

CTI BioPharma Announces The Continuation Without Modification Of PAC203 Phase 2 Study Of Pacritinib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

CTI BioPharma Announces The Continuation Without Modification Of PAC203 Phase 2 Study Of Pacritinib In Patients With Myelofibrosis Previously Treated With Ruxolitinib

SEATTLE, July 2, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned interim data review by the Independent Data Monitoring Committee (IDMC) of PAC203, the study will continue without modification and that a...

CTI BioPharma To Present At The JMP Securities 2018 Life Sciences Conference

CTI BioPharma To Present At The JMP Securities 2018 Life Sciences Conference

SEATTLE, June 14, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the JMP Securities 2018 Life Sciences Conference in New York, NY on Thursday, June 21, 2018 at 1:00 PM ET.

First Week Of CTIC July 20th Options Trading

First Week Of CTIC July 20th Options Trading

Investors in CTI BioPharma Corp saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new July 20th contracts and identified one put and one call contract of particular interest.

CTI BioPharma To Present At The Jefferies 2018 Global Healthcare Conference

CTI BioPharma To Present At The Jefferies 2018 Global Healthcare Conference

SEATTLE, June 6, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management will present at the Jefferies 2018 Global Healthcare Conference in New York, NY on Friday, June 8, 2018 at 10:30 AM ET and host...

CTI BioPharma Provides Corporate And European Regulatory Update

CTI BioPharma Provides Corporate And European Regulatory Update

- CTI BioPharma reincorporated in State of Delaware, delisted from Borsa Italiana MTA Exchange

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

TheStreet's biotech columnist offers his own report card on biotech stocks.

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

A look back at the year's worth of Adam Feuerstein's biotech tweets.

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance

Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Insider Trading Alert - LPNT, PATK And CTIC Traded By Insiders

Stocks with insider trader activity include LPNT, PATK and CTIC

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

UPCOMING DEADLINE: Levi & Korsinsky, LLP Notifies Shareholders Of CTI BioPharma Corp. Of Class Action And A Lead Plaintiff Deadline Of April 11, 2016

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp.

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

April 11 Deadline Alert: Law Offices Of Howard G. Smith Reminds CTI BioPharma Corp. Investors Of Upcoming Lead Plaintiff Deadline

Law Offices of Howard G. Smith reminds investors of the upcoming  April 11, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased CTI BioPharma Corp.

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Insider Trading Alert - SPTN, FL And CTIC Traded By Insiders

Stocks with insider trader activity include SPTN, FL and CTIC

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Stocks with insider trader activity include ATRS, CMT and CTIC

Insider Trading Alert - DRE And CTIC Traded By Insiders

Insider Trading Alert - DRE And CTIC Traded By Insiders

Stocks with insider trader activity include DRE, CTIC and WAFD

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. Investors

The Law Offices Of Howard G. Smith Announces The Filing Of A Securities Class Action On Behalf Of CTI BioPharma Corp. Investors

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CTI BioPharma Corp.

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors Of Important Deadline In Class Action - CTIC

STOCK ALERT: Rosen Law Firm Reminds CTI BioPharma Corp. Investors Of Important Deadline In Class Action - CTIC

Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp.

CTI BioPharma Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

CTI BioPharma Corp. Shareholder Alert: Former SEC Attorney Willie Briscoe And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...

Despite Many Drug Blowups, CTI Bio CEO Bianco Turns S--t Into Gold for Himself

Despite Many Drug Blowups, CTI Bio CEO Bianco Turns S--t Into Gold for Himself

In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CTI BioPharma Corp. - CTIC

EQUITY ALERT: Rosen Law Firm Announces Filing Of Securities Class Action Lawsuit Against CTI BioPharma Corp. - CTIC

Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CTI BioPharma Corp.

TheStreet Quant Rating: E+ (Sell)